基于肺生物标志物基因表达的新型mRNA疫苗质量控制安全性评估方法的开发
本研究在小鼠中腹腔或肌内注射生理盐水、流感血凝素疫苗、有毒参考流感疫苗及不同量mRNA疫苗(Spikevax或COMIRNATY),16小时后检测体重、白细胞计数、血浆细胞因子及肺生物标志物基因表达。mRNA疫苗组体重和白细胞计数较HA组显著降低,与RE组无显著差异;Spikevax组15个生物标志物中14个、COMIRNATY组全部生物标志物较HA组显著上调;部分生物标志物(Psme1、Trafd1、Lgals9、Mx2)在mRNA组显著高于RE组;mRNA疫苗组炎性细胞因子产生显著高于HA和RE组。作者认为该生物标志物评估系统对mRNA疫苗生物活性高度敏感,可用于mRNA疫苗质量控制中的安全性评估。
要点
- mRNA疫苗组体重和白细胞计数较HA组显著降低,与RE组无显著差异。
- Spikevax组15个生物标志物中14个、COMIRNATY组全部生物标志物较HA组显著上调。
- mRNA疫苗组炎性细胞因子产生显著高于HA和RE组。
核心结论
- 作者认为该基于生物标志物的评估系统对mRNA疫苗生物活性高度敏感,可用于mRNA疫苗质量控制中的安全性评估。
研究设计与样本
- 小鼠实验:分别腹腔或肌内给予生理盐水(SA)、流感血凝素(HA)疫苗、有毒参考流感疫苗(RE)及不同量mRNA疫苗(Spikevax或COMIRNATY)。
- 给药后16小时分析小鼠体重、白细胞计数、血浆细胞因子水平及肺生物标志物基因表达,并用DNA微阵列进行全基因表达分析。
主要发现
- mRNA疫苗组和RE组体重及白细胞计数较HA组显著降低,mRNA疫苗组与RE组之间无显著差异。
- Spikevax组15个生物标志物中14个、COMIRNATY组全部生物标志物较HA组显著上调。
- 部分生物标志物(Psme1、Trafd1、Lgals9、Mx2)在mRNA疫苗组显著高于RE组。
- mRNA疫苗组炎性细胞因子产生显著高于HA和RE组。
- 全基因表达分析显示mRNA疫苗接种后的基因特征,并确认多数生物标志物存在于mRNA疫苗组上调的基因集中;另发现mRNA表达水平显著升高的新基因。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this study, we tested whether our previously developed biomarker analysis could evaluate the bioactivity of SARS-Cov-2 mRNA vaccines, including their toxicity profiles. We also identified novel biomarkers that could be used to evaluate mRNA vaccine quality by analyzing global gene expression. We administered saline (SA), an influenza hemagglutinin (HA) vaccine, a toxic reference influenza vaccine (RE), and different amounts of an mRNA vaccine (Spikevax or COMIRNATY) to mice, either intraperitoneally or intramuscularly. Sixteen hours post-administration, we analyzed mouse body weight (BW), white blood cell (WBC) count, plasma cytokine levels, and biomarker gene expression in the lungs. Moreover, we performed a comprehensive gene expression analysis using DNA microarrays. BW and WBC count in the mRNA vaccine and RE groups significantly decreased compared with those in the HA group. BW and WBC count between the mRNA vaccine and RE groups did not significantly differ. In contrast, analysis of the expression levels of 15 biomarker genes revealed that 14 of the 15 biomarkers in the Spikevax group and all biomarkers in the COMIRNATY group were significantly upregulated compared with those in the HA group. The expression levels of some biomarkers (Psme1, Trafd1, Lgals9, Mx2) were significantly higher in the mRNA groups than those in the RE group. Furthermore, the mRNA vaccine groups exhibited significantly higher production of inflammatory cytokines than did the HA and RE groups. Global gene expression analysis revealed the gene signature following mRNA vaccination and confirmed that most of our biomarkers were present in the set of genes that were upregulated in the mRNA vaccine groups. In addition, we identified novel genes with significantly increased mRNA expression levels. Our results suggest that this biomarker-based evaluation system is highly sensitive to mRNA vaccine bioactivity and is useful for assessing vaccine safety in the quality control of mRNA vaccines.
引用
- Hiraga K, Momose H, Kuribayashi W, et al. Development of a novel safety assessment method for quality control of mRNA vaccines based on lung biomarker gene expression. Vaccine. 2025. PMID: 41046838. doi:10.1016/j.vaccine.2025.127805
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。